Bio-Techne (TECH)
Nasdaq Market Open
Bio-Techne Corp. is a life sciences tools and diagnostics company that supplies researchers, drug developers, clinical laboratories, and diagnostic manufacturers with specialised reagents, instruments, and testing technologies. Based in Minnesota, the company serves markets that depend on high-quality biological materials and analytical systems, including pharmaceutical research, biotechnology development, academic science, translational medicine, and clinical diagnostics.
The company operates through two main business areas: Protein Sciences and Diagnostics and Genomics. Protein Sciences is the larger segment and includes reagents, antibodies, proteins, immunoassays, cell analysis tools, and instruments used to study biological pathways and disease mechanisms. These products are important in basic research as well as in drug discovery and development, where scientists need reliable tools to measure proteins, biomarkers, and cellular activity.
Diagnostics and Genomics includes diagnostic reagents, molecular diagnostic products, controls, spatial biology tools, and technologies used in genetic and tissue-based analysis. This part of the business gives Bio-Techne exposure to clinical testing, precision medicine, and advanced research methods that examine gene and protein expression in biological samples.
Bio-Techne sells into a global customer base, with the United States representing its largest market and meaningful contributions from Europe, the Middle East, Africa, the United Kingdom, and Asia-Pacific. Its products are often embedded in customer workflows, which can support recurring demand for consumables alongside instrument placements.
The company is distinctive for combining research-use-only tools with diagnostics-related capabilities. Its performance is linked to life sciences research funding, biopharma activity, diagnostic testing trends, and demand for technologies that support more detailed analysis of disease biology.
Last updated
- Market Cap
- 7.96B
- P/E
- 72.67
- P/FCF
- 29.53
- P/S
- 6.58
- Enterprise Value
- 7.95B
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 614 MCKINLEY PL N E, MINNEAPOLIS, MN, 55413
ELISpot & FluoroSpot Assay Market Report 2026-2031: Mabtech, Oxford Immunotec Global, and Cellular Technology Dominate the Landscape
Middle East Exosomes Market Research Report 2025-2033: Diagnostic and Therapeutic Adoption, R&D Investment, and Liquid Biopsy Demand Drive Growth
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - Global Forecast to 2030
Spatial Proteomics Market Report and Competitive Landscape 2025-2030, with 10X Genomics, Bruker, Fluidigm, Akoya Biosciences, PerkinElmer, Biotechne, S2 Genomics, Seven Bridges Genomics & More
Induced Pluripotent Stem Cells Industry Poised for 9.1% CAGR Growth by 2028
Single-use Bioprocessing Probes and Sensors Market Forecast to Reach $10.95 Billion by 2034 - pH Sensors Dominate Bioprocessing Market, While Oxygen Sensors Lead Rapid Growth in Precision Biologics Monitoring
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight
CRISPR-based Gene Editing Market Report 2024-2030, Featuring Revvity, Danaher, GenScript, Merck, Tocris Bioscience, OriGene Technologies, Bio-Rad Laboratories, Bio-Techne & New England Biolabs
Apoptosis Assays Market Projected to Expand at a CAGR of 8.5%, Elevating to a Valuation of USD 11.3 billion by 2034 | Analysis by Transparency Market Research Inc.
[Latest] Global Epigenetics Diagnostic Market Size/Share - GlobeNewswire
[Latest] Global Glycomics Market Size/Share Worth USD 5.2 - GlobeNewswire
5 Stocks at the Forefront of S&P 500 ETF's Latest Rally
HRMY or TECH: Which Is the Better Value Stock Right Now?
Techne (TECH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Analysts Estimate Techne (TECH) to Report a Decline in Earnings: What to Look Out for
GSK or TECH: Which Is the Better Value Stock Right Now?
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 7.96B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 7.95B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 72.67
- P/B
P/B ratio compares a company's share price to its book value per share.
- 3.82
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 6.58
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 31.3
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 6.57
- EPS
- 0.7
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0.63%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 29.53
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 27
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 269.6M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 5.25%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 4.3%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.1
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 4.49
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 3.18
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.37
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 3.05M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 50.85
Income Statement
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Revenue | 311.42M | 295.88M | 286.56M | 316.96M | 316.18M |
| Gross profit | 208.29M | 191.28M | 188.11M | 198.81M | 214.56M |
| Operating income | 75.5M | 54.46M | 47.66M | -23.86M | 38.71M |
| EBITDA | 99.66M | 79.17M | 72M | 3.25M | 66.28M |
| Net income | 51.05M | 38.01M | 38.19M | -17.68M | 22.59M |
| Basic EPS | 0.33 | 0.24 | 0.25 | -0.11 | 0.14 |
| Diluted EPS | 0.32 | 0.24 | 0.24 | -0.11 | 0.14 |
Balance Sheet
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Total assets | 2.55B | 2.52B | 2.53B | 2.56B | 2.64B |
| Total liabilities | 465.3M | 511.71M | 560.33M | 639.06M | 626.23M |
| Total equity | 2.09B | 2.01B | 1.97B | 1.92B | 2.02B |
| Cash & equivalents | 209.82M | 172.88M | 144.96M | 162.19M | 140.67M |
| Current assets | 688.05M | 637.43M | 609.51M | 608.3M | 627.24M |
| Current liabilities | 153.28M | 140.43M | 144.55M | 175.85M | 169.2M |
Cash Flow
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Operating cash flow | 86.66M | 82.41M | 27.59M | 98.2M | 41.12M |
| Investing cash flow | -5.82M | -5.92M | 605K | 406K | -8.87M |
| Financing cash flow | -42.72M | -48.99M | -44.2M | -90.45M | -68.05M |
| Change in cash | 36.94M | 27.92M | -17.22M | 21.52M | -36.88M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SD — BIO-TECHNE Corp | View Filing | |
| edgar index | 4 — BIO-TECHNE Corp | View Filing | |
| edgar index | 144 — BIO-TECHNE Corp | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| form 4 | Form 4 — Herr Amy E. | View Filing | |
| edgar index | 4 — BIO-TECHNE Corp | View Filing | |
| edgar index | 4 — BIO-TECHNE Corp | View Filing | |
| edgar index | 4 — BIO-TECHNE Corp | View Filing | |
| edgar index | SCHEDULE 13G — BIO-TECHNE Corp | View Filing | |
| edgar index | 8-K — BIO-TECHNE Corp | View Filing | |
| edgar index | 10-Q — BIO-TECHNE Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — BIO-TECHNE Corp | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Kelderman Kim | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Bohnen Shane | View Filing | |
| form 4 | Form 4 — Hippel James | View Filing | |
| form 4 | Form 4 — Hippel James | View Filing | |
| form 4 | Form 4 — Hippel James | View Filing | |
| form 4 | Form 4 — Hippel James | View Filing | |
| form 4 | Form 4 — Hippel James | View Filing | |
| form 4 | Form 4 — Hippel James | View Filing | |
| form 4 | Form 4 — Hippel James | View Filing | |
| form 4 | Form 4 — Hippel James | View Filing | |
| form 4 | Form 4 — Hippel James | View Filing | |
| form 4 | Form 4 — Hippel James | View Filing | |
| form 4 | Form 4 — Hippel James | View Filing |